Current Headlines

  1. Alkermes And Biogen Announce U.S. Food And Drug Administration Acceptance Of Diroximel Fumarate New Drug Application For Multiple Sclerosis

    Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS)

  2. Morphic Therapeutic Enters Into Integrin Research And Development Collaboration With Janssen

    Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced recently that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies

  3. VCU College Of Engineering And Fuzionaire Diagnostics To Pursue Joint Research Applying Novel Radiochemistry Platform To Disease Diagnosis And Drug Discovery

    The Virginia Commonwealth University (VCU) College of Engineering and Fuzionaire Diagnostics (Fuzionaire Dx) have executed a research agreement establishing a collaborative program to work toward applications of Fuzionaire Dx’s proprietary radiochemistry platform

  4. MolecularMD Is Acquired By ICON

    MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of precision medicines in oncology, announced today that it has been acquired by ICON plc (NASDAQ: ICLR)

  5. PPD And HLT To Create Data Science-Driven Clinical Research Solutions In China To Enhance Global Drug Development

    Pharmaceutical Product Development, LLC (PPD) and Happy Life Tech (HLT) of China have signed an exclusive agreement to develop a distinctive service offering for the China drug-development market delivering data science-driven clinical trials and real-world evidence of drug products’ effectiveness, safety and value

  6. ADC Therapeutics Announces First Patient Dosed In Phase I Clinical Trial Of ADCT-402 (Loncastuximab Tesirine) And Ibrutinib In Patients With Advanced Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma

    ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-402 (loncastuximab tesirine) in combination with Pharmacyclics LLC’s ibrutinib in patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)

  7. ARCA Biopharma Announces FDA Agreement For A Single Phase 3 Clinical Trial To Support Approval For The First Genetically-Targeted Cardiovascular Drug

    ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of GencaroTM(bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF

  8. Evotec And Helmholtz Centre Joining Platforms And Forces For Novel Antibiotics

    Evotec AG and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens

  9. Ben-Gurion University Introduces Novel AI Platform For Monitoring And Predicting ALS Progression

    BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), disclosed today a novel artificial intelligence (AI) platform for monitoring and predicting the progression of neurodegenerative diseases for the purpose of identifying markers for personalized patient care and improved drug development

  10. Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase (MPO) inhibitor, for the treatment of multiple system atrophy (MSA)